Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | GYPA | P02724 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291876 | 1.00 | SLC6A2 (0.44) | SLC6A2PDE4DTSHRTAAR1ALDH1A1 | |
| SCHEMBL14655081 | 1.00 | SLC6A2 (0.44) | SLC6A2PDE4DTSHRTAAR1ALDH1A1 | |
| SCHEMBL15892811 | 0.98 | SLC6A2 (0.44) | SLC6A2PDE4DTSHRTAAR1ALDH1A1 | |
| SCHEMBL10978460 | 0.92 | TSHR (0.48) | SLC6A2TSHRTAAR1ALDH1A1LMNA | |
| SCHEMBL10978467 | 0.92 | TSHR (0.48) | SLC6A2TSHRTAAR1ALDH1A1LMNA | |
| SCHEMBL15892812 | 0.91 | TSHR (0.47) | SLC6A2TSHRTAAR1ALDH1A1LMNA | |
| SCHEMBL15892809 | 0.91 | TSHR (0.47) | SLC6A2TSHRTAAR1ALDH1A1LMNA | |
| SCHEMBL15658850 | 0.90 | ALDH1A1 (0.43) | SLC6A2PDE4DTSHRTAAR1ALDH1A1 | |
| SCHEMBL12770603 | 0.88 | TSHR (0.39) | SLC6A2PDE4DTSHRTAAR1ALDH1A1 | |
| SCHEMBL13156255 | 0.88 | TSHR (0.39) | SLC6A2PDE4DTSHRTAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734238-B1 | SUGAR ALCOHOL-BASED CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2020-02-19 | — | — | EP | disclosed |
| US-9907854-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9907854-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9511150-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-8907079-B2 | Crosslinking reagents, macromolecules, therapeutic conjugates, and synthetic methods thereof | CELLMOSAIC INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140206903-A1 | NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2014-07-24 | — | — | US | disclosed |
| US-4672071-A | Antihypertensive dihydropyridine compositions, optical isomers and intermediates | SYNTEX (U.S.A.) INC. (US) | 1987-06-09 | — | — | US | disclosed |
| EP-0191448-A2 | Antihypertensive dihydropyridine derivatives | SYNTEX (U.S.A.) INC. (US) | 1986-08-20 | — | — | EP | disclosed |
| US-4595690-A | Hypotensive agents | SYNTEX (U.S.A.) INC. (US) | 1986-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CD44, ADH1C, EPCAM | SLC6A2 1989/4885PDE4D 3403/4885TSHR 1244/4885 |
| US-20140206903-A1 | NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CD44, ADH1C, EPCAM | SLC6A2 1062/4885PDE4D 3509/4885TSHR 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.